AEON Biopharma regains NYSE American listing compliance after $13.6M offering

AEON Biopharma, Inc.

Received NYSE American letter confirming compliance with continued listing standards; .BC indicator to be removed.
Resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
Compliance achieved after July 2026 underwritten public offering: 17.85M shares + pre-funded warrants, net proceeds ~$13.6M.
Potential additional $34M gross proceeds from milestone warrants if fully exercised.
Company believes stockholders' equity now exceeds $4M minimum requirement.

Featured in Daily 8-K Digest

Selected #4 for 2026-08-03. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.